Arv in 2 year old
Reading File
ARVs (antiretrovirals) in a 2-year-old relates to pediatric HIV treatment. Let me search the library now.
Searching sources...
Finding Sources
Finding Sources
Searching PubMed
antiretroviral therapy children pediatric HIV
Let me search with better terms directly for ARV/HIV pediatric content in the library.
Finding Sources
Finding Sources
Searching the Web
ARV antiretroviral therapy 2 year old child WHO guidelines 2024 regimen
Reading Web Page
https://hiv.guidelines.org.au/arv-pediatric/what-start/regim…
Finding Sources
Reading Web Page
https://aahivm.org/wp-content/uploads/2025/02/Guidelines-for…
Searching the Web
WHO 2024 ARV first line regimen children under 3 years dolutegravir abacavir lamivudine
Here is a comprehensive summary of ARV (antiretroviral) therapy in a 2-year-old child with HIV, based on current guidelines (DHHS Pediatric HIV Guidelines updated June/December 2024, WHO 2021/2024 recommendations):
Antiretroviral Therapy (ARV) in a 2-Year-Old Child
When to Start ART
ART should be initiated immediately (rapid initiation) in all children with HIV, regardless of CD4 count or clinical stage. This applies to a 2-year-old as well. If diagnosis has been made but ART not yet started, monitor virologic, immunologic, and clinical status every 3-4 months and start ART as soon as possible (AI recommendation).
Regimen Structure
A standard pediatric ARV regimen consists of:
- 2 NRTIs (the "backbone") + one INSTI (preferred) or NNRTI or boosted PI
Preferred Regimens for Children Aged ≥2 Years (2024 DHHS Guidelines)
The choice depends on whether the child can swallow pills or not, and on weight.
For children who cannot swallow pills (most 2-year-olds):
| Regimen | Formulation | Weight Requirement |
|---|---|---|
| DTG + ABC + 3TC (dispersible FDC - Triumeq PD) | PREFERRED | 6 kg to <25 kg; must be HLA-B*5701 negative |
| DTG film-coated tablet (Tivicay) + ABC + 3TC/FTC in liquid | Alternative | ≥25 kg |
| BIC/FTC/TAF (Biktarvy) | Preferred | ≥14 kg (can swallow pills) |
A 2-year-old (typically 10-15 kg) who cannot swallow pills: the top choice is ABC/DTG/3TC dispersible tablets (Triumeq PD), once daily - IF HLA-B*5701 negative.
WHO Preferred Regimen (Low/Middle-Income Countries)
- ABC + DTG + 3TC - recommended as the preferred first-line regimen for pediatric patients from ≥4 weeks of age and weighing ≥3 kg, including a 2-year-old
- The pADL dispersible FDC (Abacavir 60 mg / Dolutegravir 5 mg / Lamivudine 30 mg per tablet) is the formulation being rolled out globally
Alternative Regimens for This Age Group
| Regimen | Notes |
|---|---|
| 2 NRTIs + NVP (nevirapine) | Alternative; older regimen, more toxicity |
| 2 NRTIs + LPV/r (Lopinavir/ritonavir) | Well-established in <3 years; liquid formulation available; many experts still prefer it up to age 3 |
| 2 NRTIs + RAL (raltegravir) | RAL chewable tablets for ≥2 years |
| 2 NRTIs + EFV (efavirenz) | NOT approved for <3 years |
NRTI Backbone Options
- ABC + 3TC (abacavir + lamivudine) - preferred backbone when INSTI-based; requires HLA-B*5701 testing before use
- ZDV + 3TC (zidovudine + lamivudine) - alternative; use if HLA-B*5701 positive
- TAF + FTC - for children weighing ≥14 kg
Important Practical Points for a 2-Year-Old
| Point | Detail |
|---|---|
| HLA-B*5701 testing | Mandatory before starting abacavir - hypersensitivity reaction risk |
| Formulation | Liquid, chewable, or dispersible tablets preferred (most 2-year-olds cannot swallow pills) |
| Adherence | Critical; caregiver education is essential; once-daily regimens improve adherence |
| Drug resistance testing | Do before initiating ART if possible |
| Baseline labs | CBC, LFTs, renal function, CD4 count, viral load, HLA-B*5701 |
| Follow-up | VL and CD4 at 4 weeks, 3 months, then every 3-6 months when stable |
Summary Table: Age ≥2 Years, Cannot Swallow Pills (WHO & DHHS 2024)
| Priority | Regimen | Formulation |
|---|---|---|
| PREFERRED | ABC + DTG + 3TC (if HLA-B*5701 -ve) | Triumeq PD dispersible tablet, once daily |
| Alternative | ZDV + 3TC + NVP | Liquids/syrups |
| Alternative | ABC + 3TC + LPV/r | Liquids (LPV/r widely used <3 yrs) |
| Alternative | ABC + 3TC + RAL | Chewable tabs (≥2 yrs) |
Note: Always confirm local national program guidelines, as treatment availability varies by country. ABC/DTG/3TC as dispersible tablets is the current WHO-preferred global standard for children ≥2 years.
This is a shared conversation. Sign in to Orris to start your own chat.